Department of Pharmacy, Hebei Children's Hospital, Shijiazhuang, Hebei, P.R. China.
Department of Urology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China.
Comb Chem High Throughput Screen. 2024;27(14):2078-2089. doi: 10.2174/0113862073241153231003094411.
Huangqi-Shanzhuyu (HS), a classic combination of Chinese herbal formulae, has been widely used for the treatment of diabetic nephropathy (DN). However, its pharmacological mechanism of action is still unclear.
The active ingredients of HS and their potential targets were identified through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and the DN-related targets were determined from GeneCards, Online Mendelian Inheritance in Man (OMIM), PharmGkb, and Therapeutic Target Database (TTD). The Cytoscape software was used to construct a herb-disease-target network and screen core genes. STRING was employed to generate a protein-protein interaction (PPI) network. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to predict the mechanism of action of HS in DN. Animal experiments and molecular docking were used to verify the potential mechanism.
In total, 40 active ingredients and 180 effective targets of HS in DN were identified and 1115 DN-related targets were retrieved. From the PPI network, VEGFA, AKT1, IL6, IL1B, TP53, MMP9, PTGS2, CASP3, EGF and EGFR were identified as core genes. The anti-DN mechanism mainly involved multiple signaling pathways such as AGEs-RAGE. Animal experiments and molecular docking analysis confirmed that HS downregulated the expression of IL-1 and IL-6 via kaempferol-mediated inhibition of JNK1 phosphorylation.
HS exhibits a therapeutic effect in DN through its multiple ingredients that act on several targets and multiple signaling pathways, including AGEs-RAGE.
黄芪-山茱萸(HS)是一种经典的中药方剂组合,已广泛用于治疗糖尿病肾病(DN)。然而,其药理作用机制尚不清楚。
通过中药系统药理学数据库和分析平台(TCMSP)和基因卡片、在线孟德尔遗传在线数据库(OMIM)、PharmGkb 和治疗靶点数据库(TTD)确定 HS 的活性成分及其潜在靶点,并确定与 DN 相关的靶点。使用 Cytoscape 软件构建草药-疾病-靶标网络并筛选核心基因。STRING 用于生成蛋白质-蛋白质相互作用(PPI)网络。进行基因本体论和京都基因与基因组百科全书(KEGG)富集分析,以预测 HS 在 DN 中的作用机制。动物实验和分子对接用于验证潜在机制。
共鉴定出 HS 治疗 DN 的 40 种活性成分和 180 个有效靶点,检索到 1115 个与 DN 相关的靶点。从 PPI 网络中,鉴定出 VEGFA、AKT1、IL6、IL1B、TP53、MMP9、PTGS2、CASP3、EGF 和 EGFR 为核心基因。抗 DN 机制主要涉及 AGEs-RAGE 等多种信号通路。动物实验和分子对接分析证实,HS 通过山奈酚介导的 JNK1 磷酸化抑制,下调了 IL-1 和 IL-6 的表达。
HS 通过多种成分作用于多个靶点和多个信号通路,包括 AGEs-RAGE,对 DN 表现出治疗作用。